secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001728117-22-000084
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022
--------------------------------------------------------------------------------

- Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.
- Cash, equivalents & marketable securities $222.2M as of June 30; pro forma $342M after $120M July 2022 private placement.
- Seralutinib Phase 2 TORREY topline data expected second half November or first half December 2022.
- GB5121 Phase 1b/2 STAR CNS study in PCNSL dosed first patient.
- Commencing investment in registrational Phase 3 program for seralutinib targeted for Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/0001728117-22-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/goss-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer